Skip to main content
Premium Trial:

Request an Annual Quote

Inflammatix: João Fonseca

Inflammatix has appointed João Fonseca as chief technology officer to oversee its molecular assay development and engineering teams as the firm advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification.

Since 2006, Fonseca has served as founder, CEO, and chief scientific officer of Biosurfit, a Lisbon, Portugal-based company whose blood tests diagnose multiple conditions at the point of care. The company's tests are broadly available throughout Europe.

Prior to Biosurfit, Fonseca was a professor in physics and experimental physics at the Technical University of Lisbon and a researcher at the University of Lisbon. He also founded a non-profit organization that works with patients and researchers to advance novel cancer treatments and research.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.